Condition: CLL / SLL · CLL (Chronic Lymphocytic Leukemia) · CLL, Refractory · Sponsor: Newave Pharmaceutical Inc
This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received a covalent Bruton's tyrosine kinase inhibitor (cBTKi). Approximately 306 participants will be randomized 1:1 to receive rocbrutinib 200 mg orally once daily or pirtobrutinib 200 mg orally once daily, administered continuously in 28-day cycles until disease progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria are met. Randomization will be stratified by presence of del(17p)/TP53 mutation (yes/no), reason for discontinuation of prior cBTKi therapy (toxicity vs disease progression), prior exposure to a BCL2 inhibitor (yes/no), and region (United States/China/rest of world). The primary endpoint is progression-free survival (PFS) assessed by an independent review committee (IRC) using iwCLL 2018 criteria for CLL and Lugano 2014 criteria for SLL. Key secondary objectives include overall survival, overall response rate, time-to-event outcomes, and safety/tolerability; exploratory objectives include health-related quality of life and biomarker assessments.
This description comes directly from the study's public registry record.
Anna Y Chen, M.D., Ph.D. · 1-206-335-3820 · ROCKET-CLL@newavepharma.com
Stephen Anthony, D.O. · 1-509-847-5646 · ROCKET-CLL@newavepharma.com
Always discuss trial participation with your own doctor first.
| The Center for Cancer and Blood Disorders-Bethesda | Bethesda, Maryland, United States | Recruiting |
| Optum Medical Group (Rhodes) P.C. | Las Vegas, Nevada, United States | Recruiting |
| OSU Comprehensive Cancer Center | Columbus, Ohio, United States | Not Yet Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07342478